AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03358693 — intervention group
Intervention type: DRUG
Intervention: Brodalumab
Description: Subject receives Brodalumab open-label as per guidelines
Study NCT03358693 — intervention group
Intervention type: DRUG
Intervention: Ixekizumab
Description: Subject receives Ixekizumab open-label as per guidelines
Study NCT03358693 — intervention group
Intervention type: DRUG
Intervention: Baricitinib
Description: Subject receives Baricitinib open-label as per guidelines
Study NCT03358693 — intervention group
Intervention type: DRUG
Intervention: Abrocitinib
Description: Subject receives Abrocitinib open-label as per guidelines
Study NCT03358693 — intervention group
Intervention type: DRUG
Intervention: Upadacitinib
Description: Subject receives Upadacitinib open-label as per guidelines
Study NCT03358693 — intervention group
Intervention type: DRUG
Intervention: Tralokinumab
Description: Subject receives Tralokinumab open-label as per guidelines
Study NCT04826198 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AsiDNA
Description: Unit dose: Vial containing 100 mg of AsiDNA™ (free acid) Regimen: 3 consecutive infusions (D1, D2, D3) followed by a once a week iv infusion on D8 and D15 of a 21 day-treatment cycle at first cycle, then weekly iv infusion in the absence of disease progression or unacceptable toxicity Mode/route: 1 hour intravenous (iv) infusion
Study NCT04826198 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Niraparib
Description: Unit dose: Hard capsule containing 100mg of Niraparib Regimen: The last dose given during the 6 previous months of Niraparib 200 mg/day or 300 mg/day, (or 100 mg/day only if the patient has received this dose since at least 6 months) Daily, 1, 2 or 3 hard capsules at 100mg once daily at approximately the same time each day.~Mode/route: Per os
Study NCT04826198 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olaparib
Description: Product name: Olaparib Pharmaceutical form: Tablets containing 100 or 150mg of Olaparib Route of administration: per os Dose Regimen: The last dose given during the 6 previous months of Olaparib 600 mg/day or 500 mg/day, (or 400 mg/day only if the patient has received this dose since at least 6 months) Two times daily (300mg or 250 mg or 200mg) at approximately the same time each day.
Study NCT04826198 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rucaparib
Description: Product name: Rucaparib Pharmaceutical form: Tablets containing 200 or 250 or 300mg of Rucaparib Route of administration: per os Dose Regimen: The last dose given during the 6 previous months of Rucaparib 1200 mg/day or 1000 mg/day, or 800mg/day (or 600 mg/day only if the patient has received this dose since at least 6 months) Two times daily (600mg or 500mg or 400mg or 300mg) at approximately the same time each day.
Study NCT06560944 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Combined oral contraceptive pill
Description: Ingesting their existing combined oral contraceptive pill at a specific time of day in relation to assessment of outcome measures
Study NCT06560944 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Combined oral contraceptive pill
Description: Ingesting their existing combined oral contraceptive pill at a specific time of day in relation to assessment of outcome measures
Study NCT04101344 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Two fiber-blend snack and four fiber-blend snack
Description: All subjects will complete a 47-day, multi-phase feeding study to evaluate the effect of two snack prototypes containing two different fiber blends on gut community structure and features of host biological state (plasma proteome/ metabolome).
Study NCT04224701 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BG505 SOSIP GT1.1 gp140 Vaccine, Adjuvanted
Description: 30 µg
Study NCT04224701 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BG505 SOSIP GT1.1 gp140 Vaccine, Adjuvanted
Description: 300 µg
Study NCT04224701 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Tris NaCl Diluent
Study NCT04332783 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: psychophysics of sequential biases (no drug or patient work)
Description: Psychophysical experiment on sequential effects in medical image perception. Observers, including clinicians, perform psychophysical continuous report match-to-sample and forced-choice discrimination judgments of medical images, including radiographs and photographs. Observer discrimination accuracy is measured on a trial-wise basis and sequential effects in those judgments are measured. Images can be presented with different interstimulus intervals and in different spatial locations and in different orders. Accuracy, and other signal detection metrics are computed as a function of these factors.
Study NCT03769350 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Smartphone-delivered CBT for MDD
Description: 8-week Smartphone-delivered CBT for MDD. In-person cognitive-behavioral therapy (CBT) is an empirically supported treatment for MDD. The app-delivered CBT in this project includes modules such as cognitive skills (e.g., cognitive restructuring, core belief work), behavioral activation, and perceptual retraining/mindfulness skills.
Study NCT00776204 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: JACTAX Drug eluting stent
Description: Jactax stent placed in coronary artery
Study NCT00776204 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: JACTAX LD drug eluting stent
Description: JACTAX LD stent placed in coronary artery
Study NCT00776204 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Taxus Libertè
Description: Taxus Libertè stent placed in coronary artery
Study NCT00578708 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AMPLATZER Membranous VSD Occluder
Description: Device closure with the AMPLATZER Membranous VSD Occluder
Study NCT03206775 — intervention group
Intervention type: BEHAVIORAL
Intervention: Cognitive Assessments (Phase 1)
Description: Participants will participate in up to 6 assessments in 4 domains of cognition: Processing Speed; Executive Attention; Learning and Memory; and Social Cognition.~Assessments:~* Visual Sweeps~* Sustained Visual Attention~* Associative Learning--Visual~* Associative Learning--Auditory~* Emotion Motion~* Voice Choice
Study NCT03206775 — intervention group
Intervention type: BEHAVIORAL
Intervention: Cognitive Battery A (Phase 2)
Description: Participants will complete two visual assessments, one auditory assessment, and one social cognition assessment. Then the participant will complete self-report surveys.~Assessments:~* On trails: Learning~* Line Length Discrimination~* Tap the Emotion~* Sound Sweeps~* BIS/BAS~* TEPS~* Feasibility survey
Study NCT03206775 — intervention group
Intervention type: BEHAVIORAL
Intervention: Cognitive Battery B (Phase 2)
Description: Participants will complete two visual assessments, one auditory assessment, and one social cognition assessment. Then the participant will complete the complete self-report surveys.~Assessments:~* Visual Time Order Judgment~* Target Tracker~* Emotional Face~* Auditory Sound Discrimination~* BIS/BAS~* TEPS~* Feasiblity assessment
Study NCT03206775 — intervention group
Intervention type: BEHAVIORAL
Intervention: Cognitive Battery C (Phase 2)
Description: Participants will complete two visual assessments, one auditory assessment, and one social cognition assessment. Then the participant willcomplete self-report surveys.~Assessments:~* Stroop 2AFC~* Visual Task Switcher~* Beep Seeker~* Voice Choice~* BIS/BAS~* TEPS~* Feasibility Survey
Study NCT04486911 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pyrotinib maleate, SHR6390, letrozole
Description: After providing written informed consent, the participants will undergo combined treatment of pyrotinib maleate, CDK4/6 inhibitor SHR6390, and letrozole. The effectiveness of the combined treatment will be evaluated by MRI every two treatment cycles. If the disease progresses, the participant will withdraw from the trial. If the combined treatment has identified effectiveness, the participant will undergo surgical treatment within 4 weeks (over 2 weeks) after termination of the neoadjuvant treatment. The patients will be followed up for 5 years.
Study NCT00510497 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Autologous HIV-1 ApB DC Vaccine
Description: Autologous dendritic cells pulsed with autologous, inactivated HIV-1 infected, apoptotic cells given subcutaneously 3 times every other week plus a booster dose 2 weeks after start of treatment interruption
Study NCT01706146 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Non-coumadin Oral Anticoagulant
Description: Administration of Non-coumadin Oral Anticoagulant for 30 days following episode of atrial fibrillation as detected by the Reveal XT device.
Study NCT02128971 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Ferrochel® 90 mg
Description: Ferrochel® capsule 90 mg, administered orally once daily in the morning after breakfast, for 30 days
Study NCT02128971 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Sumalate® 90 mg
Description: Sumalate® capsule 90 mg, administered orally once daily in the morning after breakfast, for 30 days
Study NCT02128971 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Ferrous fumarate 90 mg
Description: Ferrous fumarate capsule 90 mg, administered orally once daily in the morning after breakfast, for 30 days
Study NCT02128971 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Ferrous Sulfate 90 mg
Description: Ferrous Sulfate capsule 90 mg, administered orally once daily in the morning after breakfast, for 30 days
Study NCT02128971 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Ferric Glycinate 90 mg
Description: Ferric Glycinate capsule 90 mg, administered orally once daily in the morning after breakfast, for 30 days
Study NCT02128971 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Placebo capsule, administered orally once daily in the morning after breakfast, for 30 days
Study NCT04224480 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: 200mg of intravenous infusion every 3 weeks
Study NCT00932100 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: REG1
Description: IV form, bolus dose. May be redosed. Control agent given as single re-dose at completion of intervention
Study NCT02281838 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: labetalol/hydralazine/enalapril
Description: Blood pressure will be treated with intravenous labetalol (10 mg starting dose)/hydralazine (5 mg starting dose)/enalapril (1.25 mg starting dose).
Study NCT02281838 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: labetalol/hydralazine/enalapril
Description: Blood pressure will be treated with intravenous labetalol (10 mg starting dose)/hydralazine (5 mg starting dose)/enalapril (1.25 mg starting dose).
Study NCT02834884 — intervention group
Intervention type: GENETIC
Intervention: RP-1828 IMMUcan
Description: WES, lcWGS and RNAseq, multiplex IF and IMC
Study NCT02834884 — intervention group
Intervention type: GENETIC
Intervention: RP-1759 AYA/TYA
Description: WES, RNAseq and EPIC array
Study NCT02834884 — intervention group
Intervention type: GENETIC
Intervention: RP-1843 Arcagen
Description: NGS panel
Study NCT02834884 — intervention group
Intervention type: GENETIC
Intervention: RP-1920 BioRadon
Description: NGS panel
Study NCT02158091 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IPI-145
Description: oral PI3K delta/gamma inhibitor
Study NCT02158091 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: intravenous chemotherapy
Study NCT02158091 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: intravenous chemotherapy
Study NCT02158091 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: intravenous immunotherapy
Study NCT00126308 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: poly-L-lactic acid
Description: immediate injections poly-L-lactic acid (4 bilateral treatments - 8 vials)
Study NCT00126308 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: poly-L-lactic acid
Description: delayed (24 weeks) poly-L-lactic acid injections (4 bilateral treatment - 8 vials)
Study NCT01626612 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: continuation of the empirical antimicrobial therapy
Description: ALL THE ANTIBACTERIAL IN WORN SYSTEMATIC
Study NCT01626612 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: streamlining of the empirical antimicrobial therapy
Description: ALL THE ANTIBACTERIAL IN WORN SYSTEMATIC
Study NCT02887625 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pioglitazone plus exenatide
Description: pioglitazone will be started at 30 mg/day and bydureon at 2 mg/week
Study NCT03458247 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abiraterone acetate escalated dose
Description: 2000 mg/day
Study NCT01627925 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: nasal mask and continuous positive airway pressure
Description: nasal mask use instead of face mask application of continuous positive airway pressure during induction of general anesthesia
Study NCT01792414 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham TES
Description: Neuroconn Eldith device
Study NCT01792414 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Active TES
Description: Neuroconn Eldith device
Study NCT02667002 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bilateral Abdominal Sacral Hysteropexy
Description: The mesh will be fixed right and left side of sacrum.
Study NCT02667002 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Conventional abdominal Sacral Hysteropexy
Description: The mesh will be fixed only right side of sacrum
Study NCT02667002 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Nulliparous women with no uterovaginal prolapsed
Description: This will be control group which consistent patients with no uterovaginal prolapse.
Study NCT05423470 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intermittent hypoxia
Description: The intermittent hypoxia protocol will consist of three 4-minute hypoxic cycles (arterial oxygen saturation of 80%) interspersed with 4-minute normoxic cycles.
Study NCT05423470 — intervention group
Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Intermittent normoxia
Description: The intermittent normoxia protocol will consist of three 4-minute normoxic cycles (compressed air) interspersed with 4-minute normoxic cycles (room air).
Study NCT04458493 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: satiety
Description: satiety ratings, appetite and desire to eat (10-point visual analogue scale) will be measured at 30, 60 and 120 minutes after each meal replacement drink
Study NCT04458493 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Dietary Supplement: Generation UCAN supplementation
Description: meal replacement, Generation UCAN supplement, 400ml, 20% solution
Study NCT01663727 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab [Avastin]
Description: Intravenous repeating dose
Study NCT01663727 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Intravenous repeating dose
Study NCT01663727 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Intravenous repeating dose
Study NCT01316419 — intervention group
Intervention type: DRUG
Intervention: Telmisartan
Description: Telmisartan 40mg or 80mg
Study NCT01316419 — intervention group
Intervention type: DRUG
Intervention: amlodipine
Description: amlodipine 5mg or 10mg
Study NCT03994549 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Dual GLP-1/GLP-2 Receptor agonists
Description: Eight ascending doses of ZP7570
Study NCT03994549 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dual GLP-1/GLP-2 Receptor agonists
Description: Eight ascending doses of ZP7570
Study NCT02999594 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tramadol Hydrochloride
Description: 50mg intramuscularly
Study NCT02887625 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: insulin glargine and insulin aspart
Description: the dose will be escalated to maintain HbA1c \<7.0%
Study NCT03477695 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ambulatory use of the Upright device
Description: Patients will wear the UpRight for a period of two month
Study NCT02999594 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Distilled Water
Description: 2ml intramuscularly
Study NCT02536235 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: heat
Description: activated heating pad to lower abdomen
Study NCT04567576 — intervention group
Intervention type: DRUG
Intervention: Disease-modifying antirheumatic drugs (DMARDs)
Description: Within a non-experimental setting, the routine disease-modifying antirheumatic drugs (DMARDs) prescription will be evaluated as the exposure.
Study NCT04273919 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: HTC Vive with Karuna Virtual Reality Program
Description: HTC Vive head-mounted display and an HTC Vive body tracker adhered to a belt on the patient's low back, which will be placed 2 inches below the waist
Study NCT04273919 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: HTC Vive with Lumen Program
Description: HTC Vive head-mounted display with Lumen program
Study NCT01174355 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ND0801
Description: Confidential
Study NCT02480582 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Almonds
Description: Whole raw almonds provided as a mid-morning snack - 0.9g\\kg
Study NCT02480582 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cheese Savouries
Description: Cheese savoury crackers provided as a mid-morning snack - 0.9g/kg
Study NCT02801552 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PRF
Description: Regenerative Endodontic Procedure with PRF: autologous PRF will be used instead of blood clot in the second vist.
Study NCT01448356 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: temperature and humidity
Description: The volunteer is exposed to a controlled environment with a chamber setting of:~1. 25°C and 45% humidity;~2. 25°C and 65% humidity;~3. 30°C and 45% humidity;~4. 30°C and 65% humidity~After an adaptation period of at least 20 minutes, participants underwent measurements of tear evaporation and tear film break up time. After collection of data, the chamber settings were adjusted to the next condition.
Study NCT02973321 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SAR425899
Description: Self-administered by SC injection using a solution for injection in cartridge.
Study NCT02973321 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Self-administered by SC injection using a solution for injection in cartridge.
Study NCT02973321 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Liraglutide
Description: Self-administered by SC injection using a pre-filled pen.
Study NCT00932100 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Heparin
Description: IV dose per standard of care at the local institution
Study NCT01999114 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Buprenorphine transdermal patch
Description: Buprenorphine patch applied transdermally
Study NCT01999114 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Naltrexone tablet
Description: Naltrexone tablet; 1 tablet taken orally every 12 hours
Study NCT01999114 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Naltrexone tablet
Description: Naltrexone tablet; 1 tablet taken orally every 12 hours
Study NCT01999114 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos (for TDS and for naltrexone and for moxifloxacin)
Description: Matching placebos
Study NCT01999114 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Moxifloxacin tablet
Description: Moxifloxacin tablet; 1 tablet taken orally on Days 6, 13 and 17
Study NCT03499977 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sitting
Description: 10 min bouts
Study NCT03499977 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Light-Intensity Cycling
Description: 10min bout
Study NCT03499977 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Moderate-Intensity Cycling
Description: 10 min bout
Study NCT03499977 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: High-Intensity Cycling
Description: 10 min bout
Study NCT04105582 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Neo-antigen pulsed Dendritic cell
Description: Patients that have already finished their conventional treatment (chemotherapy and/or surgery) will be vaccinated with dendritic cells pulsed with synthetic peptide
Study NCT00742430 — intervention group
Intervention type: PROCEDURE
Intervention: PCI
Description: percutaneous coronary intervention in stable coronary artery disease
Study NCT02509481 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ivermectin
Study NCT02509481 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ivermectin
Study NCT02509481 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Albendazole
Study NCT02509481 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Albendazole